ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
68,049.25
0.48%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Citius Pharmaceuticals Inc (CTXR)

  7. Citius Pharmaceuticals Inc (CTXR) News

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CTXR
DateTimeSourceHeadlineSymbolCompany
29/05/202413:30PR Newswire (US)Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
21/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
21/05/202412:00PR Newswire (US)Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock SolutionNASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202421:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202421:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202421:05PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
10/05/202413:30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
30/04/202421:05PR Newswire (US)Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
26/04/202413:00PR Newswire (US)Citius Pharmaceuticals Announces $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
11/04/202413:30PR Newswire (US)Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
04/04/202413:30PR Newswire (US)Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor ConferenceNASDAQ:CTXRCitius Pharmaceuticals Inc
18/03/202412:30PR Newswire (US)Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
07/03/202413:30PR Newswire (US)Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramNASDAQ:CTXRCitius Pharmaceuticals Inc
04/03/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CTXRCitius Pharmaceuticals Inc
26/02/202412:30PR Newswire (US)Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationNASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202421:23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202421:18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202413:30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
15/02/202413:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202421:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202421:30PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202414:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202413:01PR Newswire (US)Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CTXRCitius Pharmaceuticals Inc
23/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
23/01/202413:30PR Newswire (US)Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of DirectorsNASDAQ:CTXRCitius Pharmaceuticals Inc
05/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
02/01/202421:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CTXR

Your Recent History

LSE
ZED
Zenova
LSE
KEFI
Kefi Gold And Copper
LSE
CHLL
Chill Brands
LSE
GKP
Gulf Keystone Petroleum
LSE
GOLD
LSE
POS
Plexus
LSE
KRS
Keras Resources
LSE
LLOY
Lloyds Banking
LSE
VAST
Vast Resources
LSE
VOD
Vodafone
LSE
AVCT
Avacta
LSE
RKH
Rockhopper Exploration
LSE
SAR
Sareum
LSE
TERN
Tern
LSE
GDR
Genedrive
LSE
THG
Thg
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved